

Title (en)  
CLINICAL METHODS AND PHARMACEUTICAL COMPOSITIONS EMPLOYING AMPA RECEPTOR ANTAGONISTS TO TREAT GLIOBLASTOMA AND OTHER CANCERS

Title (de)  
KLINISCHE VERFAHREN UND PHARMAZEUTISCHE ZUSAMMENSETZUNGEN MIT AMPA-REZEPTOR-ANTAGONISTEN ZUR BEHANDLUNG VON GLIOBLASTOM UND ANDEREN KARZINOMEN

Title (fr)  
MÉTHODES CLINIQUES ET COMPOSITIONS PHARMACEUTIQUES UTILISANT DES ANTAGONISTES DES RÉCEPTEURS AMPA POUR TRAITER UN GLIOBLASTOME ET D'AUTRES CANCERS

Publication  
**EP 3829567 A4 20220504 (EN)**

Application  
**EP 19841117 A 20190725**

Priority

- US 201862703951 P 20180727
- US 201962796032 P 20190123
- US 2019043525 W 20190725

Abstract (en)  
[origin: WO2020023800A1] Disclosed herein are compositions and methods employing AMPA Receptor (AMPR) antagonist compounds to treat AMPAR positive cancers in mammalian subjects. In certain detailed embodiments the AMPAR antagonist is a Perampanel compound, effective to mediate potent oncolytic effects to prevent or reduce the severity or recurrence of a variety of cancer forms, including central nervous system (CNS) cancers.

IPC 8 full level  
**A61K 31/20** (2006.01); **A61K 31/4412** (2006.01); **A61P 25/08** (2006.01)

CPC (source: EP)  
**A61K 31/05** (2013.01); **A61K 31/09** (2013.01); **A61K 31/13** (2013.01); **A61K 31/145** (2013.01); **A61K 31/155** (2013.01); **A61K 31/198** (2013.01);  
**A61K 31/352** (2013.01); **A61K 31/40** (2013.01); **A61K 31/4015** (2013.01); **A61K 31/428** (2013.01); **A61K 31/444** (2013.01);  
**A61K 31/4709** (2013.01); **A61K 31/495** (2013.01); **A61K 31/5377** (2013.01); **A61K 33/243** (2018.12); **A61K 39/395** (2013.01);  
**A61K 45/06** (2013.01); **A61P 25/08** (2017.12); **A61P 35/00** (2017.12); **C07K 16/2818** (2013.01); **A61K 2039/54** (2013.01);  
**A61K 2039/545** (2013.01)

Citation (search report)

- [X] CN 104644592 A 20150527 - TIANJIN HANKANG PHARMACEUTICAL BIOTECHNOLOGY CO LTD
- [X] WO 2016172333 A1 20161027 - TEVA PHARMACEUTICALS INT GMBH [CH], et al
- [XI] IZUMOTO SHUICHI ET AL: "Seizures and Tumor Progression in Glioma Patients with Uncontrollable Epilepsy Treated with Perampanel", ANTICANCER RESEARCH, vol. 38, no. 7, 1 July 2018 (2018-07-01), GR, pages 4361 - 4366, XP055904927, ISSN: 0250-7005, Retrieved from the Internet <URL:<https://ar.iiarjournals.org/content/anticanres/38/7/4361.full.pdf>> DOI: 10.21873/anticanres.12737
- See references of WO 2020023800A1

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)  
**WO 2020023800 A1 20200130**; AU 2019310122 A1 20210318; CA 3145507 A1 20200130; EP 3829567 A1 20210609; EP 3829567 A4 20220504

DOCDB simple family (application)  
**US 2019043525 W 20190725**; AU 2019310122 A 20190725; CA 3145507 A 20190725; EP 19841117 A 20190725